Event Description

Premal Shah's career has spanned both academia and industry, he spent over six years as an Assistant Professor of Genetics at Rutgers University, where he was a member of the Human Genetics Institute of New Jersey and led research on the dynamics and evolution of gene regulation and protein synthesis. Since transitioning to industry in 2022, he has held Director-level roles at Ananke Therapeutics and a stealth-mode biotech firm, where he led computational biology, RNA design, and target discovery efforts to advance the next generation of RNA-based therapeutics. SanegeneBio is a global biotech with a singular vision: Best-in-class RNAi medicines. They are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Their proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Throughout his career, he has built and led interdisciplinary teams of molecular biologists, computer scientists, and statisticians, integrating high-throughput genomics with bioinformatics and computational approaches. 

Click here to see slides.